Invests in companies deriving revenue from psychedelic drugs and derivatives. Focuses on publicly listed life sciences companies in the psychedelic medicine space. Now — the numbers.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It paid $1.68 per share over the last 12 months, with payments going back years without a break — regular cash for whoever holds the stock.
The stock trades 79% below its five-year peak.
We grade companies — revenue, margins, balance sheets. This is a fund, so there is no report card to give. That is not a low grade; it is a different kind of thing.
One-line summary: a basket, not a business. Judge it by what it holds.